04:52 PM EDT, 08/15/2024 (MT Newswires) -- Vericel ( VCEL ) said Thursday the US Food and Drug Administration has approved NexoBrid for eschar removal in pediatric patients with deep partial-thickness and/or full-thickness thermal burns.

The company said it's expanding its target client base to include the about 20 pediatric burn centers in the US.

Price: 47.05, Change: +0.91, Percent Change: +1.97